|
|
 |
|
Viewing report
|
|
|
|
Competitor Analysis: Insulin
La Merie, Oct 2008, Pages: 69
This Competitive Intelligence report on insulin provides a competitor analysis in the development pipeline of novel insulin-based products for treatment of type 1 and 2 diabetes. The report also includes the diabetes R&D portfolios of those companies with emerging diabetes drugs (incl. R&D projects for established targets).
Insulin therapy has evolved in the last century from purified bovine or porcine insulin to biosynthetic human insulin to recombinant human insulin and eventually to recombinant insulin analogs as the 3rd generation of human insulin. The worldwide market of the major human insulin products in 2007 was US$ 10.2 billion. Insulin analogs posted double digit sales growth due to successive replacement (67.5 % of total sales) of 2nd generation human insulin. Three companies dominate the worldwide insulin market, but experience more and more competition in volume sales of insulin by local manufacturers in off-patent countries, especially in China, India and Russia. The first Indian company is conducting clinical trials in the US with its rhu insulin and even plans to develop and launch a biosimilar insulin analog in the Western countries upon patent expiry in 2014. Three companies in off-patent countries have locally produced insulin analogs either in the market or in pre-registration phases.
The next generations of insulin will be “tailored” insulin and oral insulin. Tailored insulin analogs and other long-acting insulins for injection with drug delivery solutions. aim at optimized pharmacokinetic profiles in order to avoid hyper- and hypo-glycemic episodes. After the failure of inhaled insulin (only one clinical stage project left), most of the R&D efforts are now made on oral insulin products. The pipeline of oral insulin shows at least seven different oral insulin formulations in clinical development, and at least six in preclinical development. The first oral insulin product is already marketed and in advanced registration in many countries. Further six different projects with non-injectable drug delivery of insulin are in clinical development: intranasal, transdermal and rectal application.
The Competitor Analysis Insulin also provides the insulin product portfolios and R&D pipelines of major players from Big Pharma, leading insulin players in off-patent countries and specialty biotech companies.
Customers who bought this item also bought
Pipeline Insight: Insulin Antidiabetics - Return to Injections - Alternative Delivery Methods Fall by the Wayside
Impact of Inhaled Insulin on the Insulin Market
The World Diabetes Market, 2007-2025: An analysis of Diabetes Drug and Insulin Market
Market Research of Diabetes and its Treatment Medicine-Insulin in China, 2008
Competitor Analysis: Diabetes Drug Pipeline
Insulin Delivery Systems Market Analysis (2008-2012)
Insulin Delivery Systems Market Analysis (2007-2010)
Chinese Markets for Insulin
Insulin Pumps (External) - Global Strategic Business Report
Pipeline Insight: Non-Insulin Antidiabetics – Incretin Mimetics – Leaders in a Diverse Pipeline
Insulin Pumps Pipeline Technology And Market Forecasts To 2015
Stakeholder Insight: Insulin Use in Type 2 Diabetes - From Last Resort to Early Intervention
|
|
|
|
